1. Search Result
Search Result
Results for "

fibrinolysis

" in MedChemExpress (MCE) Product Catalog:

17

Inhibitors & Agonists

1

Biochemical Assay Reagents

2

Peptides

3

Natural
Products

1

Recombinant Proteins

2

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-101918

    Thrombin Cardiovascular Disease
    DS-1040 Tosylate is an orally active, selective inhibitor of activated thrombin-activatable fibrinolysis inhibitor (TAFIa) with IC50s of 5.92 nM and 8.01 nM for human and rat TAFIa. DS-1040 Tosylate is a fibrinolysis enhancer for thromboembolic diseases .
    DS-1040 Tosylate
  • HY-B0236
    6-Aminocaproic acid
    2 Publications Verification

    EACA; Epsilon-Amino-n-caproic Acid; 6-Aminohexanoic acid

    PAI-1 Metabolic Disease Cancer
    6-Aminocaproic acid (EACA), a monoamino carboxylic acid, is a potent and orally active inhibitor of plasmin and plasminogen. 6-Aminocaproic acid is a potent antifibrinolytic agent. 6-Aminocaproic acid prevents clot lysis through the competitive binding of lysine residues on plasminogen, inhibiting plasmin formation and reducing fibrinolysis. 6-Aminocaproic acid can be used for the research of bleeding disorders .
    6-Aminocaproic acid
  • HY-124577

    PAI-1 Cardiovascular Disease
    MDI-2268 is an inhibitor of plasma kallikrein inhibitor 1 (PAI-1). MDI-2268 has good antithrombotic properties and regulates blood coagulation and fibrinolysis process by enhancing fibrinolysis. MDI-2268 can be used in research areas such as deep vein thrombosis .
    MDI-2268
  • HY-E70524

    PAI-1 Cardiovascular Disease
    Alpha 2 Antiplasmin, Human Plasma is Alpha-2 antiplasmin from human plasma. Alpha-2 antiplasmin is the major circulating inhibitor of plasmin. Alpha-2 antiplasmin plays a determining role in the regulation of intravascular fibrinolysis .
    Alpha 2 Antiplasmin, Human Plasma
  • HY-B0236A

    EACA hydrochloride; Epsilon-Amino-n-caproic Acid hydrochloride; 6-Aminohexanoic acid hydrochloride

    Drug Derivative PAI-1 Metabolic Disease Cancer
    6-Aminocaproic acid hydrochloride, a monoamino carboxylic acid, is a potent and orally active inhibitor of plasmin and plasminogen. 6-Aminocaproic acid is a potent antifibrinolytic agent. 6-Aminocaproic acid prevents clot lysis through the competitive binding of lysine residues on plasminogen, inhibiting plasmin formation and reducing fibrinolysis. 6-Aminocaproic acid can be used for the research of bleeding disorders .
    6-Aminocaproic acid hydrochloride
  • HY-B0236R

    EACA(Standard); Epsilon-Amino-n-caproic Acid(Standard); 6-Aminohexanoic acid (Standard)

    PAI-1 Others Metabolic Disease Cancer
    6-Aminocaproic acid (Standard) is the analytical standard of 6-Aminocaproic acid. This product is intended for research and analytical applications. 6-Aminocaproic acid (EACA), a monoamino carboxylic acid, is a potent and orally active inhibitor of plasmin and plasminogen. 6-Aminocaproic acid is a potent antifibrinolytic agent. 6-Aminocaproic acid prevents clot lysis through the competitive binding of lysine residues on plasminogen, inhibiting plasmin formation and reducing fibrinolysis. 6-Aminocaproic acid can be used for the research of bleeding disorders .
    6-Aminocaproic acid (Standard)
  • HY-E70393D

    Others Others
    Human Factor Alpha XIIa is a blood coagulation protease, which increases the clotting potential. Human Factor Alpha XIIa exhibits a fibrinolysis protein homologous heavy chain, indicating its function in fibrinolysis .
    Human Factor Alpha XIIa
  • HY-142163

    Thrombin Cardiovascular Disease
    S62798 is a selective and potent inhibitor of activated thrombin activatable fibrinolysis inhibitor (TAFIa) with an IC50 value of 6 mM.
    S62798
  • HY-E70550

    Biochemical Assay Reagents Cardiovascular Disease
    Human Prekallikrein is a single-chain gamma globulin glycoprotein involved in contact activation, kinin formation, and the early stages of fibrinolysis .
    Human Prekallikrein
  • HY-P5356

    Plasmin substrate

    Fluorescent Dye Others
    H-D-Val-Leu-Lys-AFC (Plasmin substrate) is a biological active peptide. (This is a fluorescent plasmin substrate, Abs/Em=380/500 nm.Plasmin belongs to the family of serine proteases. It plays a key role in fibrinolysis by dissolving fibrin in blood clots. Besides fibrinolysis, plasmin is also involved in such physiological and pathological processes as wound healing, liver repair, and the maintenance of liver homeostasis.)
    H-D-Val-Leu-Lys-AFC
  • HY-105940

    Amino Acid Derivatives Cardiovascular Disease
    IQB-782 is a cysteine derivative. IQB-782 has inhibition for thrombin activatable fibrinolysis inhibitor (TAFI), with an Ki(app) of 0.14 μM. IQB-782 shows a potent mucolytic-expectorant activity .
    IQB-782
  • HY-119160

    PAI-1 Inflammation/Immunology Cancer
    TM5007 is a poent and orally active inhibitor of plasminogen activator inhibitor-1 (PAI-1) with an IC50 of 29 μM. TM5007 enhance fibrinolysis activity and inhibits coagulation. TM5007 also prevents the fibrotic process initiated by bleomycin in mouse lung .
    TM5007
  • HY-12586

    Thrombin Others
    AZD6564 is an orally active inhibitor for fibrinolysis through disruption of plasma kinase-fibrin interaction. AZD6564 dissolves human plasma clot with an IC50 of 0.44 μM. AZD6564 ameliorates hemorrhage in rats with EC50 of 1.62 μM, and exhibits good pharmacokinetic characteristics in rats .
    AZD6564
  • HY-107802

    Breviscapinun

    NF-κB Interleukin Related Cardiovascular Disease
    Breviscapine is a crude flavonoid extract of Breviscapine, which is more than 85% of the active ingredient, Breviscapine. Breviscapine has a wide range of cardiovascular pharmacological activities, such as increasing blood flow, improving microcirculation, dilating blood vessels, reducing blood viscosity, promoting fibrinolysis, inhibiting platelet aggregation and thrombosis. Breviscapine has been used in the study of cerebral infarction and its sequelae, cerebral thrombosis, coronary heart disease and angina pectoris .
    Breviscapine
  • HY-B0236S

    EACA-d6; Epsilon-Amino-n-caproic acid-d6; 6-Aminohexanoic acid-d6

    Isotope-Labeled Compounds Metabolic Disease
    6-Aminocaproic acid-d6 is deuterium labeled 6-Aminocaproic acid. 6-Aminocaproic acid (EACA), a monoamino carboxylic acid, is a potent and orally active inhibitor of plasmin and plasminogen. 6-Aminocaproic acid is a potent antifibrinolytic agent. 6-Aminocaproic acid prevents clot lysis through the competitive binding of lysine residues on plasminogen, inhibiting plasmin formation and reducing fibrinolysis. 6-Aminocaproic acid can be used for the research of bleeding disorders[1][2].
    6-Aminocaproic acid-d6
  • HY-B0236S1

    EACA-d10; Epsilon-Amino-n-caproic Acid-d10; 6-Aminohexanoic acid-d10

    Isotope-Labeled Compounds Metabolic Disease
    6-Aminocaproic acid-d10 is the deuterium labeled 6-Aminocaproic acid. 6-Aminocaproic acid (EACA), a monoamino carboxylic acid, is a potent and orally active inhibitor of plasmin and plasminogen. 6-Aminocaproic acid is a potent antifibrinolytic agent. 6-Aminocaproic acid prevents clot lysis through the competitive binding of lysine residues on plasminogen, inhibiting plasmin formation and reducing fibrinolysis. 6-Aminocaproic acid can be used for the research of bleeding disorders[1][2].
    6-Aminocaproic acid-d10
  • HY-120516

    PAI-1 Cardiovascular Disease
    CDE-096 is a potent inhibitor of PAI-1. CDE-096 prevents PAI-1 from inactivating tPA and uPA with similar potency (IC50=30 and 25 nM, respectively) and is active against glycosylated PAI-1, as well as PAI-1 derived from several species (IC50=19, 22 and 18 nM for murine, rat, and Porcine PAI-1, respectively) .
    CDE-096

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: